| 21.1 0.66 (3.23%) | 05-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 28.41 | 1-year : | 33.19 |
| Resists | First : | 24.32 | Second : | 28.41 |
| Pivot price | 19.18 |
|||
| Supports | First : | 19.31 | Second : | 16.2 |
| MAs | MA(5) : | 19.4 |
MA(20) : | 19.43 |
| MA(100) : | 20.37  |
MA(250) : | 25.24 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 32.8 |
D(3) : | 24.6 |
| RSI | RSI(14): 61.6 |
|||
| 52-week | High : | 35.95 | Low : | 16.04 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SMTI ] has closed above the upper band by 11.7%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 11.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 22.15 - 22.25 | 22.25 - 22.35 |
| Low: | 20.23 - 20.35 | 20.35 - 20.46 |
| Close: | 20.9 - 21.1 | 21.1 - 21.28 |
Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako's Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako's Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako's Antimicrobial Skin and Wound Irrigation Solution. The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Wed, 13 May 2026
Sanara MedTech Inc. (NASDAQ:SMTI) Q1 2026 Earnings Call Transcript - Insider Monkey
Tue, 12 May 2026
Sanara MedTech Inc (SMTI) Q1 2026 Earnings Call Highlights: Stro - GuruFocus
Mon, 11 May 2026
Sanara MedTech Reports Q1 2026: Revenue $27.8M, GAAP Net Income $0.05/share, Adjusted EBITDA $4.3M - TradingView
Mon, 11 May 2026
Sanara MedTech (SMTI) posts Q1 profit, backs 13–17% 2026 growth - Stock Titan
Mon, 11 May 2026
Sanara MedTech sees 13-17% 2026 sales growth after 19% Q1 jump - Stock Titan
Mon, 11 May 2026
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sanara MedTech Inc. (SMTI) And Encourages Stockholders to Connect - ACCESS Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 9 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 53.2 (%) |
| Held by Institutions | 13.5 (%) |
| Shares Short | 261 (K) |
| Shares Short P.Month | 217 (K) |
| EPS | -0.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.66 |
| Profit Margin | -36.5 % |
| Operating Margin | 10.5 % |
| Return on Assets (ttm) | 7 % |
| Return on Equity (ttm) | -1.8 % |
| Qtrly Rev. Growth | 4.6 % |
| Gross Profit (p.s.) | 10.43 |
| Sales Per Share | 11.25 |
| EBITDA (p.s.) | 1.28 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 7 (M) |
| Levered Free Cash Flow | 9 (M) |
| PE Ratio | -422 |
| PEG Ratio | 0 |
| Price to Book value | 31.96 |
| Price to Sales | 1.87 |
| Price to Cash Flow | 28.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|